De Loof, Hans

De Meyer, Guido

De Ridder, Dirk

Kockx, Mark M.

Marien, Koen

Martinet, Wim

Scherer, Stefan J.

Ung, Christopher

Waelput, Wim

Abstract: Bevacizumab is the first anti-angiogenic agent approved for the treatment of metastatic colorectal cancer. The need for patient selection before initiating therapy necessitates the study of various proteins expressed in metastatic colorectal cancer tissue as candidate predictive markers. Immunohistochemistry is a valuable, commonly available and cost-effective method to assess predictive biomarkers. However, it is subject to variations and therefore requires rigorous protocol standardizations. Furthermore, validated quantification methodologies to study these angiogenic elements have to be applied. Based on their function in tumor angiogenesis and their relation to the mechanism of action of bevacizumab, protein markers were divided in four groups: VEGF A-signaling proteins; other relevant angiogenesis factors; factors regarding the tumor microenvironment and tumor intrinsic markers. Conceivably, nimbly selecting a small but relevant group of therapy-guided patients by the appropriate combination of predictive biomarkers may confer great value to this angiogenic inhibitor

Institutional Repository Universiteit Antwerpen

Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer : an update

Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer : an update

Abstract

Similar works

Full text

Available Versions

Institutional Repository Universiteit Antwerpen